1
|
Rapaport E. Utilization of ATP administration for the treatment of cancer and AIDS. Expert Opin Investig Drugs 2008. [DOI: 10.1517/13543784.3.4.379] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
2
|
Capasso A. Adenosine receptors are involved in the control of acute naloxone-precipitated withdrawal: in vitro evidence. Life Sci 2000; 66:873-83. [PMID: 10714888 DOI: 10.1016/s0024-3205(99)00671-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
The effects exerted by adenosine A1 and A2 receptor agonists and antagonists on the acute opiate withdrawal induced by morphine were investigated in vitro. Following a 4 min in vitro exposure to morphine, the guinea-pig isolated ileum exhibited a strong contracture after the addition of naloxone. The P1 adenosine receptor agonist, adenosine, was able to reduce dose-dependently naloxone-precipitaded withdrawal. The same effect was induced by the adenosine A1 receptor agonist, N6-Cyclopentyladenosine (CPA) whereas the selective adenosine A2A receptor agonist CGS 21680 increased the naloxone-precipitated withdrawal phenomenon. Dipyridamole, a blocker of adenosine reuptake, induced a significant reduction of morphine dependence. Caffeine, an adenosine receptor antagonist, significantly increased the naloxone-precipitated withdrawal effect in a concentration dependent manner. The same effect was observed with 8-phenyltheophylline (8PT), an A1 adenosine receptor antagonist, whereas 3,7-dimethyl-1-propargylxanthine (DMPX), an A2 adenosine receptor antagonist, reduced the naloxone-precipitated withdrawal phenomenon. The results of our experiments indicate that both A1 and A2 adenosine receptor agonists and antagonists are able to influence opiate withdrawal in vitro, suggesting an important functional interaction between the adenosine receptors and opioid withdrawal.
Collapse
Affiliation(s)
- A Capasso
- Department of Pharmaceutical Sciences, University of Salerno, Fisciano, Italia.
| |
Collapse
|
3
|
Dixon DA, Fenix LA, Kim DM, Raffa RB. Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists. Ann Pharmacother 1999; 33:480-8. [PMID: 10332540 DOI: 10.1345/aph.18215] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
OBJECTIVE To review preclinical and clinical information related to pharmacologic modulation of dopamine D2 receptors as potential novel antipsychotic therapy. Specifically, to summarize the data that suggest a modulatory action of adenosine A2A receptors on dopamine D2 receptors and, therefore, a possible rational role of adenosine A2A agonists as novel antipsychotic agents. DATA SOURCES Primary and review articles were identified by MEDLINE search (from 1966 to May 1998) and through secondary sources. STUDY SELECTION AND DATA EXTRACTION All of the articles identified from the data sources were evaluated and all information deemed relevant was included in this review. DATA SYNTHESIS For all of the older and many of the newer antipsychotic agents, there is a strong correlation between clinical antipsychotic activity and affinity for dopamine D2 receptors. Unfortunately, dopamine D2 receptors are believed to also be involved in the adverse effect profile of these agents. The indirect modulation of dopamine D2 receptors, rather than direct block, might produce antipsychotic effects without the usual adverse reactions. Several lines of evidence from animal studies suggest that the use of selective A2A agonists might represent a novel approach to the treatment of psychoses. CONCLUSIONS Dopamine receptor modulation might represent a novel antipsychotic approach or adjunct therapy. The data regarding adenosine agonists (particularly selective A2A receptor agonists) are inconclusive at the present time. Direct clinical demonstration of effectiveness is required.
Collapse
Affiliation(s)
- D A Dixon
- School of Pharmacy, Temple University, Philadelphia, PA 19140, USA
| | | | | | | |
Collapse
|
4
|
Varani K, Gessi S, Dalpiaz A, Ongini E, Borea PA. Characterization of A2A adenosine receptors in human lymphocyte membranes by [3H]-SCH 58261 binding. Br J Pharmacol 1997; 122:386-92. [PMID: 9313951 PMCID: PMC1564935 DOI: 10.1038/sj.bjp.0701378] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
1. The present study describes for the first time the characterization of the adenosine A2A receptor in human lymphocyte membranes with the new potent and selective antagonist radioligand, [3H]-5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo [4,3-e]-1,2,4 triazolo [1,5-c] pyrimidine, ([3H]-SCH 58261). In addition, both receptor affinity and potency of reference adenosine receptor agonists and antagonists were determined in binding and adenylyl cyclase studies. 2. Saturation experiments revealed a single class of binding sites with Kd and Bmax values of 0.85 nM and 35 fmol mg-1 protein, respectively. A series of adenosine receptor ligands were found to compete for the binding of 0.8 nM [3H]-SCH 58261 to human lymphocyte membranes with a rank order of potency consistent with that typically found for interactions with the A2A-adenosine receptor. In the adenylyl cyclase assay the same compounds exhibited a rank order of potency similar to that observed in binding experiments. 3. Thermodynamic data indicate that [3H]-SCH 58261 binding to human lymphocytes is entropy and enthalpy-driven, a finding in agreement with the thermodynamic behaviour of antagonists for rat striatal A2A-adenosine receptors. 4. It is concluded that in human lymphocyte membranes [3H]-SCH 58261 directly labels binding sites showing the characteristic properties of the adenosine A2A-receptor. The presence of A2A-receptors in peripheral tissue such as human lymphocytes strongly suggests an important role for adenosine in modulating immune and inflammatory responses.
Collapse
Affiliation(s)
- K Varani
- Department of Clinical and Experimental Medicine, University of Ferrara, Italy
| | | | | | | | | |
Collapse
|
5
|
Lorenzen A, Grossekatthöfer B, Kerst B, Vogt H, Fein T, Schwabe U. Characterization of a novel adenosine binding protein sensitive to cyclic AMP in rat brain cytosolic and particulate fractions. Biochem Pharmacol 1996; 52:1375-85. [PMID: 8937447 DOI: 10.1016/s0006-2952(96)00465-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
A novel binding site for the adenosine receptor agonist 5'-N-ethylcarboxamidoadenosine (NECA), which was enriched in rat forebrain, was characterized in cytosolic and particulate preparations. The site showed a pharmacological profile different from other [3H]NECA binding proteins and was named adenotin 2. [3H]NECA was bound in the presence of 100 microM 2-chloroadenosine with a Kd of 45.4 nM and a Bmax of 4711 fmol/mg in the cytosol and a Kd of 72.4 nM and a Bmax of 4844 fmol/mg in the crude membrane fraction. The presence of two different binding sites on adenotin 2 for [3H]NECA was shown in kinetic experiments. This protein showed identical pharmacological profiles in both subcellular preparations. [3H]NECA was displaced by purine analogues with a rank order of potency of NECA > 3'5' cyclic AMP (cAMP) > 5'-deoxy-5'-chloroadenosine > S-adenosylhomocysteine approximately 5'-deoxy-5'-methylthioadenosine (MeSA) > adenosine approximately adenine. cAMP inhibited [3H]NECA binding allosterically, whereas adenine and MeSA acted competitively. Inhibitors and activators of protein kinases such as N-(2-aminoethyl)-5-isoquinolinesulfonamide, Sp-adenosine cyclic monophophothioate and (8R*, 9S*, 11S*)-(-)-9-hydroxy-9-methoxy -carbonyl-8-methyl-2,3,9, 10-tetrahydro-8,11-epoxy-1H, 8H, 11H-2, 7b, 11a-triazadibenzo-(a,g)cycloocta(cde)-trinden-1-one (K 252a) interacted with [3H]NECA binding to adenotin 2 in nanomolar concentrations. Adenosine-5'-O-(3-thiotriphosphate) (100 microM) increased the affinity of [3H]NECA to a Kd of 9 nM and diminished the affinity of cAMP. The pharmacological characteristics of this novel binding site for [3H]NECA resemble those of the inhibition of phosphorylation processes by adenosine and its derivatives in heart and smooth muscle but are distinct from known adenosine receptors, adenosine binding proteins and protein kinases.
Collapse
Affiliation(s)
- A Lorenzen
- Pharmakologisches Institut der Universität Heidelberg, Germany
| | | | | | | | | | | |
Collapse
|
6
|
|
7
|
Gasior M, Borowicz K, Kleinrok Z, Czuczwar SJ. Chronic caffeine and the anticonvulsant potency of antiepileptic drugs against maximal electroshock. Pharmacol Biochem Behav 1996; 54:639-44. [PMID: 8853183 DOI: 10.1016/0091-3057(95)02222-8] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The anticonvulsant activities of intraperitoneally (IP) given carbamazepine (CBZ) or diphenylhydantoin (DPH), expressed as their respective ED50 values in mg/kg, were assessed after caffeine (CAFF) treatment against maximal electroshock-induced seizures in mice. CAFF was administered IP either in a single dose or every 12 h for 3 (subchronic CAFF) and 14 days (chronic CAFF). Moreover, the protective activity of the antiepileptics was determined in mice which, following chronic CAFF, received a challenge dose of CAFF after either 24 or 72 h since CAFF withdrawal. A significant reduction of the protective efficacy of CBZ was observed after chronic CAFF treatment (in a dose of 11.55 mg/kg), while a single dose and a 3-day treatment did not alter the action of CBZ. In case of CAFF (23.1 mg/kg), a significant elevation of CBZ's ED50 value was noted after 3- and 14-day treatments with CAFF. In contrast, chronic CAFF (23.1-46.2 mg/kg) decreased the anticonvulsive activity of DPH to the same extent as did acute CAFF. Moreover the ED50 values for both, CBZ and DPH, evaluated 24 h after a 14-day treatment with CAFF (in doses of 23.1 and 46.2 mg/kg, respectively), were significantly elevated compared to respective control groups. A strong impairment of the anticon-vulsant action of CBZ and DPH was observed when a challenge dose of CAFF was injected following either 24 or 72 h injection-free time. Pharmacokinetic interactions do not seem to explain the obtained results in terms of total plasma levels of the antiepileptics after chronic treatment with CAFF. Our results may suggest that epileptic patients should avoid CAFF-containing beverages and medicines.
Collapse
Affiliation(s)
- M Gasior
- Department of Pharmacology, Medical University School, Lublin, Poland
| | | | | | | |
Collapse
|
8
|
Varani K, Gessi S, Dalpiaz A, Borea PA. Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]-CGS 21680 binding. Br J Pharmacol 1996; 117:1693-701. [PMID: 8732278 PMCID: PMC1909568 DOI: 10.1111/j.1476-5381.1996.tb15341.x] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
1. The binding properties of human platelet A2a adenosine receptors, assayed with the A2a-selective agonist, [3H]-2-[p-(2-carboxyethyl)-phenethylamino]-5'-N-ethylcarboxamidoad enosine ([3H]-CGS 21680), are masked by a non-receptorial component, the adenotin site. In order to separate A2a receptors from adenotin sites, human platelet membranes were solubilized with 1% 3-[(3-cholamidopropyl)dimethyl-ammonio]-1-propanesulphonate (CHAPS). The soluble platelet extract was precipitated with polyethylene glycol (PEG) and the fraction enriched in adenosine receptors was isolated from the precipitate by differential centrifugation. 2. The present paper describes the binding characteristics of the selective A2a agonist, [3H]-CGS 21680, to this purified platelet membrane preparation. In addition, receptor affinity and potency of several adenosine agonists and antagonists were determined in binding and adenylyl cyclase studies. 3. Saturation experiments revealed a single class of binding site with Kd and Bmax values of 285 nM and 2.07 pmol mg-1 of protein respectively. Adenosine receptor ligands competed for the binding of 50 nM [3H]-CGS 21680 to purified protein, showing a rank order of potency consistent with that typically found for interactions with the A2a adenosine receptors. In the adenylyl cyclase assay the compounds examined exhibited a rank order of potency very close to that observed in binding experiments. 4. Thermodynamic data indicated that [3H]-CGS 21680 binding to the purified receptor is totally entropy-driven in agreement with results obtained in rat striatal A2a adenosine receptors. 5. It is concluded that in the purified platelet membranes there is a CGS 21680 binding site showing the characteristic properties of the A2a receptor. This makes it possible to use this compound for reliable radioligand binding studies on the A2a adenosine receptor of human platelets.
Collapse
Affiliation(s)
- K Varani
- Institute of Pharmacology, University of Ferrara, Italy
| | | | | | | |
Collapse
|
9
|
Abstract
The effects of chronic ethanol exposure on the stress-like protein adenotin were investigated using the radioligand [3H]-5'-N-ethylcarboxamidoadenosine ([3H]NECA). A 4-day exposure to 150 mM ethanol increased both the KD and the density of [3H]NECA binding sites. These changes were not due to residual ethanol as the acute addition of ethanol did not alter [3H]NECA binding. Chronic ethanol exposure of A126-1B2-1 cells, which are a mutant PC 12 cell line deficient in protein kinase A (PKA), increased the cellular density of adenotin, but did not affect the KD for the radioligand. Conversely, when PC 12 cells were exposed to 10 microM forskolin for either 2 or 4 days, the cellular density of adenotin was not altered, but the affinity of adenotin for [3H]NECA was reduced significantly. An increase in KD was not observed after a 1-hr exposure of PC 12 cells to forskolin, indicating that the reduction in affinity for the radioligand was not due simply to a PKA-mediated phosphorylation of adenotin. The present study demonstrated that chronic ethanol regulates adenotin through two different mechanisms. The ethanol-induced increase in the density of adenotin does not involve PKA, while the reduction in affinity ap pears to involve a cAMP-dependent mechanism.
Collapse
Affiliation(s)
- R A Rabin
- Department of Pharmacology and Toxicology, Suny at Buffalo, NY 14214-3000, USA
| |
Collapse
|
10
|
Kafka SH, Corbett R. Selective adenosine A2A receptor/dopamine D2 receptor interactions in animal models of schizophrenia. Eur J Pharmacol 1996; 295:147-54. [PMID: 8720578 DOI: 10.1016/0014-2999(95)00668-0] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
In the apomorphine-induced climbing mouse assay, the potencies of the selective adenosine A1 receptor agonist, N6-cyclohexyladenosine (CHA), and the selective A2A adenosine receptor agonist, 2-p-(2-carboxyethyl) phenethylamino 5'-N-ethyl-carboxamidoadenosine (CGS 21680), and various dopamine receptor antagonists were as follows: SCH 23390 = haloperidol > raclopride > CHA = CGS 21680. While in catalepsy, their potencies were SCH 23390 > haloperidol > raclopride > CGS 21680. CHA failed to induce catalepsy due to significant sedation/ataxia. The combined administration of the ED15 dose of CHA failed to potentiate the ED50 value of SCH 23390, raclopride, or haloperidol in the apomorphine-induced climbing mouse assay. However, the combined administration of the ED15 dose of CGS 21680 significantly decreased the ED50 of raclopride by 8.0-fold and haloperidol by 35-fold. The adenosine A2A receptor antagonist, 1,3,7-trimethyl-8-(3-chlorostyryl)xanthine (CSC), significantly decreased catalepsy induced by raclopride and haloperidol, while the adenosine A1 receptor antagonist, 1,3-dimethyl-8-phenylxanthine (8-PT), was ineffective. The present results show that in behavioral assays predictive for antipsychotic activity, adenosine receptor agonists block behaviors in a similar manner to dopamine receptor antagonists.
Collapse
Affiliation(s)
- S H Kafka
- Neuroscience PGU, Hoechst-Roussel Pharmaceuticals, Inc., Somerville, NJ 08876, USA
| | | |
Collapse
|
11
|
Abstract
The identification and characterization of adenosine receptors and the development of potent, receptor subtype-selective agonists and antagonists has been an active area of research for the past 20 years. Major recent advances in the field have been the cloning of several adenosine receptor subtypes of different species, including the discovery of a new subtype, designated A3, the discovery and development of new agonists and antagonists, particularly those with selectivity for the A2a adenosine receptor, the characterization of signal transduction pathways, and the development of agents which act indirectly on the adenosine receptor system. The present article focusses on aspects of pharmaceutical/medicinal chemistry related to adenosine receptors.
Collapse
Affiliation(s)
- C E Müller
- Pharmazeutisches Institut, Pharmazeutische Chemie, Tübingen, Germany
| | | |
Collapse
|
12
|
Jarvis MF, Saltzman A. [3H]5?-N-Ethylcarboxamidoadenosine selectively labels the low affinity adenosine binding protein, adenotin, on intact chinese hamster ovary cells. Drug Dev Res 1993. [DOI: 10.1002/ddr.430290409] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
13
|
Abbracchio MP, Cattabeni F, Fredholm BB, Williams M. Purinoceptor nomenclature: A status report. Drug Dev Res 1993. [DOI: 10.1002/ddr.430280304] [Citation(s) in RCA: 76] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|